Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab), the first biologic medication for adults with moderate to severe atopic dermatitis (AD) for whom other topical treatments have not worked or are not advised.
Different from topical or oral medications, biologic drugs or “biologics” are made from proteins typically derived from human DNA and “grown” through a sophisticated manufacturing process.
Dupixent works by blocking proteins called interleukins, or ILs, from attaching to cell receptors. Interleukins contribute to a functioning immune system by helping to fight off viruses or bacteria in our bodies. When the immune system goes haywire, it can trigger certain ILs to mistakenly attack the body, resulting in chronic, inflammatory conditions such as atopic dermatitis.
Dupixent works on two interleukins thought to contribute to atopic diseases: IL-4 and IL-13. By blocking IL-4 and IL-13 from binding to its receptors, Dupixent curbs the immune system over-reaction that results in atopic dermatitis. A calmed immune system leads to fewer and/or less severe symptoms of AD.
In clinical trials, Dupixent was shown to reduce symptoms of AD such as itching, redness, lichenification (thickened skin), swelling, and scratched skin. Dupixent is given by 300 mg injection every other week after a starting dose of 600 mg. Dupixent is available by prescription only.
For more information please call 1-844-Dupixent (1-844-387-4936), visit www.dupixent.com and talk to your doctor.